ArticleTherapeutic innovation & regulatory science2026
Strategic Integration of Companion Diagnostics in Precision Oncology: Key Factors, Drug Development Timelines, and Regulatory Insights from U.S. FDA Approvals.
Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCompanion diagnostics (CDxs) are central to precision oncology, enabling identification of patients most likely to benefit from targeted therapies. Their quantitative impact on anticancer drug development timelines and regulatory outcomes has not been fully defined, and co-development often poses logistical and regulatory challenges.
methodsWe reviewed 354 oncology indications across 127 anticancer drugs approved by the U.S. Food and Drug Administration between 2014 and 2024. Indications were classified by CDx requirement. Clinical, molecular, and regulatory features were compared between CDx and non-CDx indications. Multivariable logistic regression analysis identified factors associated with CDx adoption, and multivariable linear regression restricted to new molecular entities assessed associations with development timelines.
resultsCDx-associated approvals increased steadily, comprising 43% of all oncology indications by 2022. CDx use was significantly associated with low-prevalence biomarkers (odds ratio [OR] 49.07), intermediate-prevalence biomarkers (OR 6.88), enzyme targets (OR 14.56), kinase targets (OR 5.18), and solid tumors (OR 3.65) compared with high-prevalence biomarkers, receptor targets, and hematologic tumors. Neither sponsor size nor orphan drug designation influenced CDx adoption. In regression models of new molecular entities, CDx presence was associated with a mean reduction in development time of 379.5 days (p = 0.006), similar in magnitude to Breakthrough Therapy Designation. Accelerated timelines were largely attributable to increased likelihood of early-phase approvals.
conclusionCDx co-development enriches trial populations and facilitates initial approvals, particularly for molecularly defined solid tumors with low- or intermediate-prevalence biomarkers. Early, indication-specific integration of CDx, combined with regulatory accelerators, provides a pragmatic strategy to enhance trial efficiency, shorten development timelines, and expand timely patient access to life-prolonging therapies.
Indexed as
Identifiers
41845174What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.